Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 12/20 | 0.48 |
| ▸ | XIAP | P98170 | 12/20 | 0.47 |
| ▸ | BIRC3 | Q13489 | 5/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471950 | 1.00 | BIRC2 (0.48) | BIRC2XIAPBIRC3RIPK2 | |
| SCHEMBL21106900 | 1.00 | BIRC2 (0.48) | BIRC2XIAPBIRC3RIPK2 | |
| SCHEMBL21471951 | 1.00 | BIRC2 (0.48) | BIRC2XIAPBIRC3RIPK2 | |
| SCHEMBL28788354 | 1.00 | BIRC2 (0.48) | BIRC2XIAPBIRC3RIPK2 | |
| SCHEMBL29312021 | 0.93 | BIRC2 (0.46) | BIRC2XIAPBIRC3RIPK2 | |
| SCHEMBL23572024 | 0.92 | TRPV1 (0.42) | BIRC2XIAPBIRC3 | |
| Lcl-161 SCHEMBL21064744 | 0.92 | XIAP (0.50) | BIRC2XIAPBIRC3RIPK2 | |
| Lcl-161 SCHEMBL1275554 | 0.92 | XIAP (0.50) | BIRC2XIAPBIRC3RIPK2 | |
| Lcl-161 SCHEMBL19164873 | 0.92 | XIAP (0.50) | BIRC2XIAPBIRC3RIPK2 | |
| Lcl-161 SCHEMBL3688581 | 0.92 | XIAP (0.50) | BIRC2XIAPBIRC3RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250269042-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES AND USES IN TREATING NEUROLOGICAL DISEASES | BIOXEL INC. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250213706-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES | BIOXEL INC. (US) | 2025-07-03 | — | — | US | claimed |
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | claimed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | claimed |
| US-8207183-B2 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | claimed |
| US-20110281875-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | claimed |
| CN-1964970-B | Inhibitors of iap | NOVARTIS AG | 2011-08-03 | — | — | CN | claimed |
| US-20250269042-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES AND USES IN TREATING NEUROLOGICAL DISEASES | BIOXEL INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250213706-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES | BIOXEL INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024059041-A1 | BENZO-FUSED N-HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20110281875-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| EP-2065368-A1 | Inhibitors of IAP | Novartis Ag (CH) | 2009-06-03 | — | — | EP | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213706-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES | PSMA6, PSMA1, CUL2 | BIRC2 173/4885XIAP 23/4885BIRC3 166/4885 |
| US-20080242658-A1 | Inhibitors of Iap | XIAP, BIRC2, BIRC5 | BIRC2 2/4885XIAP 1/4885BIRC3 5/4885 |
| US-20250269042-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES AND USES IN TREATING NEUROLOGICAL DISEASES | ADRM1, UCHL1, UCHL3 | BIRC2 211/4885XIAP 14/4885BIRC3 221/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | BIRC2 426/4885XIAP 541/4885BIRC3 506/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | BIRC2 762/4885XIAP 191/4885BIRC3 580/4885 |
| US-20110281875-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | BIRC2 2/4885XIAP 5/4885BIRC3 6/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | BIRC2 3250/4885XIAP 1017/4885BIRC3 3691/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BIRC2 218/4885XIAP 74/4885BIRC3 144/4885 |
| US-20120207769-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | BIRC2 2/4885XIAP 5/4885BIRC3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.